touchHAEMATOLOGY touchHAEMATOLOGY
Rare Diseases
Watch Time: 13 mins

Phase III APPLY-PNH and APPOINT-PNH trials investigate iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria, 48-week data: Phillip Scheinberg, ASH 2023

Copy Link
Published Online: Feb 7th 2024

The 48-week data from the phase III APPLY-PNH and APPOINT-PNH trials investigates iptacopan, a first oral proximal complement inhibitor targeting factor B, in patients with paroxysmal nocturnal haemoglobinuria. We met with Dr Phillip Scheinberg (Hospital A Beneficência Portuguesa, São Paulo, Brazil) to discuss the data, and he reports the proportion of patients with clinical breakthrough haemolysis, exposure-adjusted occurrence rates and clinical breakthrough haemolysis characteristics during iptacopan monotherapy in the Phase III APPLY-PNH and APPOINT-PNH trials.

The abstract entitled ‘Clinical Breakthrough Hemolysis (BTH) during Monotherapy with the Oral Factor B Inhibitor Iptacopan Is Generally Not Severe and Managed without Treatment Discontinuation: 48-Week Data from the Phase III APPLY-PNH and APPOINT-PNH Trials in Paroxysmal Nocturnal Hemoglobinuria (PNH)‘ was presented at the 65th ASH Annual Meeting and Exposition December 9-12, 2023, in San Diego, CA, USA.

Please note correction: Cross-over in the APPLY-PNH trial was at 24 weeks, not 12 weeks as described in the interview (6:00)

Questions

  1. Could you describe the current treatment landscape for paroxysmal nocturnal haemoglobinuria (PNH) and how breakthrough haemolysis presents a challenge? (0:36)
  2. What is the rationale for the use of iptacopan as a monotherapy in the APPLY-PNH and APPOINT-PNH trials, and how does its mechanism target PNH? (2:49)
  3. What were the design and primary objectives of these phase III trials? (5:16)
  4. What were the key findings of the trials? (7:09)
  5. Based on these trial results, what are the implications for iptacopan’s role in future PNH treatment strategies? (9:42)

Disclosures: Phillip Scheinberg is a consultant for Abbvie, Amgen, AstraZeneca, BioCryst, Janssen, Novartis, Roche; and has received grant/research support from Pfizer, Alnylam; and is on advisory boards for Astellas, Novartis, Pfizer, Roche, Teva; and has received honoraria/honorarium from Abbvie, Alexion, Bristol Myers Squibb, Jannsen, Novartis, Pfizer; and is a speaker’s bureau participant with Novartis, Roche, Pfizer, Alexion.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.

Filmed in coverage of the ASH 2023

Click here for more content on paroxysmal nocturnal haemoglobinuria

Share this Video
Related Videos In Rare Diseases
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72